moneyheap
CI · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is The Cigna Group (CI) stock moving?
Cigna beat Q3 estimates on Nov 5 with $7.98 adjusted EPS against about $7.50 expected and $73.7B revenue, and raised 2026 adjusted EPS to at least $30.60. The stock still sold off hard: it hit an intraday high of $318.05 on Nov 5 on 2.77M shares, then closed at $301.48 and fell to $293.59 on Nov 6 on 2.43M shares. Management flagged 2027 headwinds, including about $200M from exiting the ACA exchange market, pressure on pharmacy rebate pools, lower employer GLP-1 coverage and a thinner biosimilar pipeline, while still guiding to at least 10% adjusted EPS growth in 2027. Analysts remain mostly constructive, with price targets of $320 (Barclays Equal-Weight, Evercore In-Line), $340 (Cantor Overweight) and $347 (Guggenheim Buy, lowered). The stock recovered from $295.60 on Nov 9 to $303.13 on Nov 10 on 1.49M shares, still below the pre-earnings level of about $315 on Oct 22. The long-term 10%-14% EPS CAGR target and $3B cost program support the bull case, but the 2027 headwinds and the post-earnings selling keep the near-term picture mixed.
News behind the analysis
- The Cigna Group Reports Strong Third Quarter 2026 Results, Raises 2026 OutlookQ3 2026 total revenue rose 6% to $73.7B and adjusted EPS was $7.98. The company raised its 2026 adjusted EPS outlook to at least $30.60 and set 10%-14% adjusted EPS CAGR targets through 2030.
- Cigna Tops Q3 Estimates, Raises 2026 Outlook as It Flags 2027 HeadwindsCigna beat Q3 estimates with $7.98 adjusted EPS on $73.7B revenue and still expects at least 10% EPS growth in 2027. The company flagged 2027 headwinds from its ACA exit and pharmacy benefit pressures.
- Cigna Exec Says Expects About $200M Headwind In 2027 From Exiting Affordable Care Act Exchange MarketManagement expects roughly $200M of 2027 headwind from exiting the ACA exchange business. This is a known cost that weighs on next-year earnings visibility.
- Cigna Continues To Expect Adjusted EPS Growth Of At Least 10% In 2027 Off Its Run-RateCigna reaffirmed at least 10% adjusted EPS growth for 2027 off its run-rate. It also flagged headwinds from rebate pool compression, lower GLP-1 coverage and a thinner biosimilar pipeline.
- Cigna Delivers Strong Q3, Accelerate To One Program Targets $3B Savings By 2030Shares fell after Q3 results, but analysts stayed constructive, citing raised guidance, 2027 growth and strong demand. The $3B Accelerate to One program is the main new cost initiative.
- Guggenheim Maintains Buy on Cigna Group, Lowers Price Target to $347Guggenheim kept its Buy rating and cut its price target to $347. The move signals that the stock still has a sizable upside view from a Buy-rated analyst.
- Cantor Fitzgerald Reiterates Overweight on Cigna Group, Maintains $340 Price TargetCantor Fitzgerald reiterated its Overweight rating and kept a $340 price target. The analyst view supports upside from current levels.
- Evercore ISI Group Maintains In-Line on Cigna Group, Raises Price Target to $320Evercore ISI kept an In-Line rating and raised its price target to $320. The rating stays neutral while the target moves up.
- Barclays Maintains Equal-Weight on Cigna Group, Raises Price Target to $320Barclays kept an Equal-Weight rating and raised its price target from $310 to $320. The target is close to the last close of $303.13.
- The Cigna Group Announces Participation in 2026 UBS Global Healthcare ConferenceCFO Ann Dennison will present at the 2026 UBS Global Healthcare Conference. The event gives management another public forum to discuss the outlook.
About The Cigna Group
The Cigna Group is a US health company based in Bloomfield, Connecticut. It runs two businesses: Evernorth Health Services, which includes the Express Scripts pharmacy benefit manager and the Accredo specialty pharmacy, and Cigna Healthcare, which sells health insurance mainly to employers. What sets it apart from most insurers is that the pharmacy services side brings in most of its revenue, and its insurance business focuses on employer plans rather than Medicare.
How it makes money
Evernorth brings in the large majority of revenue, roughly 85% to 90% (about $64 billion of roughly $72 billion in a recent quarter). It earns this by managing drug benefits for employers and health plans, running specialty and mail-order pharmacies, and providing care services. Cigna Healthcare makes up the rest of revenue (about $12 billion a quarter). It collects premiums and fees from employer-sponsored medical, dental and other plans in the US and abroad. Profits are split more evenly than revenue because insurance has higher margins. The company expects about $280 billion in adjusted revenue for 2026.
What usually moves CI
- Pharmacy benefit manager (PBM) regulation and drug-rebate reform
- Specialty drug and GLP-1 weight-loss drug trends
- Employer medical cost trends
- Renewals and losses of large PBM clients
- Share buybacks and earnings guidance